<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In inflammatory <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> and <z:mp ids='MP_0001856'>myocarditis</z:mp> there is-apart from <z:hpo ids='HP_0001635'>heart failure</z:hpo> and antiarrhythmic therapies-no alternative to an aetiologically driven specific treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Prerequisite are noninvasive and invasive biomarkers including endomyocardial biopsy and PCR on cardiotropic agents </plain></SENT>
<SENT sid="2" pm="."><plain>This review deals with the different etiologies of <z:mp ids='MP_0001856'>myocarditis</z:mp> and inflammatory <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> including the genetic background, the predisposition for <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>It analyses the epidemiologic shift in pathogenetic agents in the last 20Â years, the role of innate and aquired immunity including the T- and B-cell driven immune responses </plain></SENT>
<SENT sid="4" pm="."><plain>The phases and clinical faces of <z:mp ids='MP_0001856'>myocarditis</z:mp> are summarized </plain></SENT>
<SENT sid="5" pm="."><plain>Up-to-date information on current treatment options starting with <z:hpo ids='HP_0001635'>heart failure</z:hpo> and antiarrhythmic therapy are provided </plain></SENT>
<SENT sid="6" pm="."><plain>Although <z:mp ids='MP_0001845'>inflammation</z:mp> can resolve spontaneously, specific treatment directed to the causative aetiology is often required </plain></SENT>
<SENT sid="7" pm="."><plain>For fulminant, <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> autoreactive <z:mp ids='MP_0001856'>myocarditis</z:mp> immunosuppressive treatment is beneficial, while for <z:mp ids='MP_0001799'>viral</z:mp> <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:mp ids='MP_0001856'>myocarditis</z:mp> ivIg can resolve <z:mp ids='MP_0001845'>inflammation</z:mp> and is as successful as interferon therapy in enteroviral and adenoviral <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>For Parvo B19 and HHV6 <z:mp ids='MP_0001856'>myocarditis</z:mp> eradication of the virus is still a problem by any of these treatment options </plain></SENT>
<SENT sid="9" pm="."><plain>Finally, the potential of stem cell therapy has to be tested in future trials </plain></SENT>
<SENT sid="10" pm="."><plain>In virus-negative, autoreactive perimyocardial disease a locoregional approach with intrapericardial instillation of high local doses of triamcinolone <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> has been shown to be highly efficient and with few systemic side-effects </plain></SENT>
</text></document>